Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants
  1. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024 | M  CDC
  2. RSV shot for infants 90 percent effective against hospitalizations: CDC  The Hill
  3. CDC says new treatment for infant RSV infections ‘highly effective’ in preventing hospitalization  WSB Atlanta
  4. Only nine percent of older Americans were vaccinated against RSV before the disease hit this fall and winter  Medical Xpress
  5. RSV monoclonal Beyfortus was 90% effective at preventing hospitalizations in children this winter: CDC  STAT

You can read the full story here: Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants .

Share this post :

Facebook
Twitter
LinkedIn
Pinterest

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News